Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-linea ABOSTO:QLINEA -2.50%66 Quick Ratio is 106.15 as of Jun. 2026, which is 1934% above its 10-year median of 5.22. GuruFocus rates OSTO:QLINEA with a GF Score™ of 66/100 and a GF Value™ of kr19.19 (Fairly Valued). The stock has 3 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Q-linea AB ranks better than 99.53% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Q-linea AB's quick ratio for the quarter that ended in Jun. 2026 was 106.15.
Q-linea AB has a quick ratio of 106.15. It generally indicates good short-term financial strength.
The historical rank and industry rank for Q-linea AB's Quick Ratio or its related term are showing as below:
OSTO:QLINEA'
s Quick Ratio Range Over the Past 10 Years
Min: 0.41 Med: 5.22 Max: 106.15
Current: 106.15
During the past 11 years, Q-linea AB's highest Quick Ratio was 106.15. The lowest was 0.41. And the median was 5.22.
OSTO:QLINEA's Quick Ratio is ranked better than 99.53% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 1.88
vs OSTO:QLINEA: 106.15
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Q-linea AB Quick Ratio Related Terms
Q-linea AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for Q-linea AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:QLINEA vs ABT, SYK, MDT: Quick Ratio Comparison
For the Medical Devices subindustry, Q-linea AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Q-linea AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Q-linea AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (OSTO:QLINEA) has a Quick Ratio of 106.15 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Q-linea AB and its competitors. This is 1934% above median its historical median of 5.22. Over the past decade, Q-linea AB's Quick Ratio has ranged from 0.41 to 106.15. According to the industry distribution chart, Q-linea AB ranks #4 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 0.5%.
Is Q-linea AB's Quick Ratio too high?
Q-linea AB's current Quick Ratio of 106.15 is 1934% above median its 10-year median of 5.22. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 106.15. The Medical Devices & Instruments industry median Quick Ratio is 1.88. Q-linea AB's value of 106.15 is 5546.3% above this industry median. Based on the distribution chart, Q-linea AB ranks #4 out of 851 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-linea AB has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Quick Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #4 out of 851 companies for Quick Ratio. This places Q-linea AB in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.88. Q-linea AB's value of 106.15 is 5546.3% above this benchmark. Historically, Q-linea AB's own Quick Ratio has ranged from 0.41 to 106.15 over the past decade. While the company's 10-year median is 5.22 vs. the industry median of 1.88, Q-linea AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.88, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-linea AB's current Quick Ratio of 106.15 is 5546.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current Quick Ratio is 106.15, which is 1934% above median its own 10-year median of 5.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Based on GuruFocus' analysis, Q-linea AB (OSTO:QLINEA) is currently considered Fairly Valued. The stock's GF Value™ is kr19.19, compared to a current price of kr17.55 — trading 8.5% below its estimated fair value. The current Quick Ratio is 106.15, which is 1934% above median its 10-year median of 5.22 and 5546.3% above the Medical Devices & Instruments industry median of 1.88. Q-linea AB's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Q-linea AB (OSTO:QLINEA), the current Quick Ratio is 106.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (OSTO:QLINEA) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr17.55 is trading 8.5% below its estimated GF Value™ of kr19.19.
GuruFocus considers Q-linea AB to be Fairly Valued.
Key valuation signals for OSTO:QLINEA:
Quick Ratio: 106.15 (1934% above median its 10-year median of 5.22)
GF Value™: kr19.19 vs. price of kr17.55 (8.5% below fair value)
Industry Position: 5546.3% above the Medical Devices & Instruments median (#4 of 851)
No single metric tells the full story. See the OSTO:QLINEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
66GF Score
Get the complete analysis for OSTO:QLINEA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:QLINEA has been successfully added to your 
